COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies (Nasdaq: CLGN) announced it will report third quarter 2025 financial results on Wednesday, November 26, 2025, before the U.S. market open. The company develops non-animal-derived rhCollagen products for tissue regeneration and medical aesthetics. Investors can expect the company to release results and any accompanying commentary or materials on that date.
CollPlant Biotechnologies (Nasdaq: CLGN) ha annunciato che riferirà i risultati finanziari del terzo trimestre 2025 mercoledì 26 novembre 2025, prima dell'apertura del mercato statunitense. L'azienda sviluppa prodotti rhCollagen non derivati da animali per la rigenerazione dei tessuti e l'estetica medica. Gli investitori possono aspettarsi che l'azienda renda noti i risultati ed eventuali commenti o materiali correlati in quella data.
CollPlant Biotechnologies (Nasdaq: CLGN) anunció que informará los resultados financieros del tercer trimestre de 2025 el miércoles 26 de noviembre de 2025, antes de la apertura del mercado estadounidense. La empresa desarrolla productos rhCollagen no derivados de animales para la regeneración de tejidos y la estética médica. Los inversores pueden esperar que la empresa publique los resultados y cualquier comentario o material adjunto ese día.
CollPlant Biotechnologies (Nasdaq: CLGN)는 2025년 3분기 재무 실적을 2025년 11월 26일 수요일 미국 시장 개장 전에 발표할 예정이라고 발표했습니다. 회사는 동물 유래가 없는 rhCollagen 제품을 조직 재생 및 의료 미용을 위한 분야에서 개발합니다. 투자자들은 그 날짜에 회사가 결과와 함께 제공될 모든 해설이나 자료를 발표할 것으로 기대할 수 있습니다.
CollPlant Biotechnologies (Nasdaq: CLGN) a annoncé qu'elle publiera les résultats financiers du troisième trimestre 2025 le mercredi 26 novembre 2025, avant l'ouverture du marché américain. L'entreprise développe des produits rhCollagen non dérivés d'origine animale pour la régénération tissulaire et l'esthétique médicale. Les investisseurs peuvent s'attendre à ce que l'entreprise publie les résultats et tout commentaire ou matériel associé à cette date.
CollPlant Biotechnologies (Nasdaq: CLGN) gab bekannt, dass es die Finanzergebnisse des dritten Quartals 2025 am Mittwoch, dem 26. November 2025 vor der US-Handelsöffnung berichten wird. Das Unternehmen entwickelt rhCollagen-Produkte, die nicht tierischen Ursprungs sind für Gewebe regeneration und medizinische Ästhetik. Investoren können erwarten, dass das Unternehmen zu diesem Datum Ergebnisse sowie entsprechende Begleitkommentare oder Unterlagen veröffentlicht.
CollPlant Biotechnologies (ناسداك: CLGN) أعلنت أنها ستعلن عن نتائجها المالية للربع الثالث من عام 2025 يوم الأربعاء 26 نوفمبر 2025، قبل افتتاح السوق الأمريكية. تطور الشركة منتجات rhCollagen غير المشتقة من الحيوانات لإعادة تشكيل الأنسجة والجمالية الطبية. يمكن للمستثمرين توقع أن تقوم الشركة بنشر النتائج وأي تعليقات أو مواد مرافقة في ذلك التاريخ.
- None.
- None.
REHOVOT,
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com
Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-2025-third-quarter-financial-results-302618450.html
SOURCE CollPlant